Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis. Guenin S, Andrews E, Lebwohl MG. Br J Dermatol 2023 Nov 27:ljad473. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Guenin S, Andrews E, Lebwohl MG. Safety and Efficacy of Dual TYK2 Inhibitor and Monoclonal Antibody Therapy for Psoriasis and Psoriatic Arthritis. Br J Dermatol 2023 Nov 27:ljad473. doi: 10.1093.
PMID: 38011328